

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 September 2021 (02.09.2021)



(10) International Publication Number
WO 2021/174048 A1

(51) International Patent Classification:

C07F 9/38 (2006.01) A61K 31/10 (2006.01)
C07F 9/32 (2006.01) A61P 3/00 (2006.01)
A61K 31/662 (2006.01) A61P 1/06 (2006.01)
A61K 31/675 (2006.01)

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(21) International Application Number:

PCT/US2021/019975

(22) International Filing Date:

26 February 2021 (26.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/983,438 28 February 2020 (28.02.2020) US
63/076,113 09 September 2020 (09.09.2020) US
63/117,074 23 November 2020 (23.11.2020) US
63/147,980 10 February 2021 (10.02.2021) US

(71) Applicant: **KALLYOPE, INC.** [US/US]; 430 East 29th Street, 10th Floor, New York, New York 10016 (US).

(72) Inventors: **SEBHAT, Iyassu**; 430 East 29th Street, 10th Floor, New York, New York 10016 (US). **HE, Shuwen**; 430 East 29th Street, 10th Floor, New York, New York 10016 (US).

(74) Agent: **BAGULEY, Tyler D.**; Wilson Sonsini, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: GPR40 AGONISTS

(57) Abstract: This disclosure is directed, at least in part, to GPR40 agonists useful for the treatment of conditions or disorders involving the gut-brain axis. In some embodiments, the GPR40 agonists are gut-restricted compounds. In some embodiments, the GPR40 agonists are full agonists or partial agonists. In some embodiments, the condition or disorder is a metabolic disorder, such as diabetes, obesity, nonalcoholic steatohepatitis (NASH), or a nutritional disorder such as short bowel syndrome.



WO 2021/174048 A1